Melitracen

Melitracen

SCHEMBL48975

CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 8/20 1.00
SLC6A2 P23975 7/20 1.00
KCNH2 Q12809 7/20 1.00
HTR2B P41595 6/20 1.00
CHRM2 P08172 6/20 1.00
CHRM1 P11229 6/20 1.00
DRD2 P14416 6/20 1.00
SLC6A4 P31645 6/20 1.00
ADRA1A P35348 6/20 1.00
DRD3 P35462 6/20 1.00
ADRA2C P18825 5/20 1.00
CHRM3 P20309 5/20 1.00
HTR2A P28223 5/20 1.00
HTR2C P28335 5/20 1.00
HTR1A P08908 5/20 1.00
ADRA2A P08913 5/20 1.00
ADRA2B P18089 4/20 1.00
DRD1 P21728 4/20 1.00
MC3R P41968 4/20 1.00
HRH3 Q9Y5N1 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Melitracen SCHEMBL29984590 1.00 HRH1 (1.00) HRH1SLC6A2KCNH2HTR2BCHRM2
Melitracen SCHEMBL121493 0.98 HRH1 (0.97) HRH1SLC6A2KCNH2HTR2BCHRM2
Melitracen SCHEMBL29399425 0.98 HRH1 (0.97) HRH1SLC6A2KCNH2HTR2BCHRM2
Melitracen SCHEMBL2473296 0.98 HRH1 (0.97) HRH1SLC6A2KCNH2HTR2BCHRM2
Melitracen SCHEMBL1650139 0.97 HRH1 (0.94) HRH1SLC6A2KCNH2HTR2BCHRM2
Melitracen SCHEMBL29195738 0.97 HRH1 (0.94) HRH1SLC6A2KCNH2HTR2BCHRM2
Litracen SCHEMBL2109078 0.77 SLC6A2 (0.62) HRH1SLC6A2KCNH2HTR2BCHRM2
Cyclobenzaprine SCHEMBL38527 0.76 HRH1 (1.00) HRH1SLC6A2KCNH2HTR2BCHRM2
Cyclobenzaprine SCHEMBL29520569 0.76 HRH1 (1.00) HRH1SLC6A2KCNH2HTR2BCHRM2
Cyclobenzaprine SCHEMBL7654526 0.76 HRH1 (1.00) HRH1SLC6A2KCNH2HTR2BCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3460 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706649-A1 USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS BIOPROJET (FR) 2026-03-11 EP claimed
US-20260034065-A1 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2026-02-05 US claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
US-12496300-B2 Methods of treating acute depression and anxiety INTRA-CELLULAR THERAPIES, INC. (US) 2025-12-16 US claimed
US-12472146-B2 Extended release pharmaceutical formulation DOUGLAS PHARMACEUTICALS, LTD. (NZ) 2025-11-18 US claimed
US-20250295674-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS SAGE THERAPEUTICS, INC. 2025-09-25 US claimed
US-20250238922-A1 MACHINE-LEARNING SYSTEM FOR DIAGNOSING DISORDERS AND DISEASES AND DETERMINING DRUG RESPONSIVENESS Sanford Burnham Prebys Medical Discovery Institute 2025-07-24 US claimed
US-12350379-B2 Extended release pharmaceutical formulation and methods of treatment DOUGLAS PHARMACETICALS LTD (NZ) 2025-07-08 US claimed
US-20250177418-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS SAGE THERAPEUTICS, INC. 2025-06-05 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-6010715-A SUSTAINED DRUG RELEASE; MONOLITHIC CARRIER BERTEK, INC. (US) 2000-01-04 US claimed
US-5922341-A Local administration of pharmacologically active agents to treat premature ejaculation VIVUS, INCORPORATED (US) 1999-07-13 US claimed
EP-0563507-B1 Transdermal patch incorporating a polymer film incorporated with an active agent BERTEK INC (US) 1998-05-27 EP claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 WO claimed
US-5679373-A MELT-BLENDING THERMOPLASTIC MATRIX; IMPERMEABLE BACKING; LAMINATION WITHOUT ADHESIVE; CONTROLLED RELEASE BERTEK, INC. (US) 1997-10-21 US claimed
US-5662926-A SOLVENT FREE BERTEK, INC. (US) 1997-09-02 US claimed
EP-0563507-A1 Transdermal patch incorporating a polymer film incorporated with an active agent MLI ACQUISITION CORP. II (US) 1993-10-06 EP claimed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 EP claimed